To read the full story
Related Article
- J&J’s Lazcluze, Genmab’s Tivdak and More Drugs in Line for Japan Approval
February 28, 2025
- J&J’s Lazcluze, Genmab’s Tivdak, and More Up for MHLW Panel Review on Feb. 27
February 14, 2025
- Janssen Files Amivantamab for Post-Tagrisso NSCLC Setting in Japan
June 3, 2024
- Janssen Primed to Join Japan Lung Cancer Market with Doublet Now under Review
April 26, 2024
- Janssen Files Bispecific Antibody Amivantamab for NSCLC in Japan
November 20, 2023
BUSINESS
- Santen to Launch Myopia Drug in April; Will Its Private-Care Use Spread in Children?
March 21, 2025
- Otsuka/Taiho Look to Leverage Araris’ Linker Tech to Create 1st-in-Class ADCs
March 21, 2025
- Nippon Kayaku’s Humira Biosimilar Adds nr-axSpA Use
March 21, 2025
- New BMS Japan Chief Vows Bold Resource Allocation towards Doubling of Sales
March 21, 2025
- Datroway, Zeposia, and More Meds Now Available in Japan; Zepbound Launch Set for April 11
March 21, 2025
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…